The Vercoulen lab publishes new findings which can help predict melanoma patient response to anti-PD-1 treatment

Written By Aniek Janssen

The authors find that monocyte-derived macrophages (MDMs) and cytotoxic T-cells in the tumor microenvironment can help predict who will benefit from anti–PD-1 treatment. This suggests that MDM infiltration could be a new biomarker to guide personalized immunotherapy and improve survival outcomes. Read more: https://www.nature.com/articles/s41416-025-03137-8

Aniek Janssen
Previous

Collaborative paper on landscaping immune infiltrates in pediatric Hepatoblastoma by the Peng (PMC) and Vercoulen (CMM) labs published

Next

Sonia Aristin Revilla from the Coffer lab publishes findings on CD4+ T cell differentiation in 3D cell culture hydrogels.